Comparison of Efficacy and Specificity in Cancer-Targeting Prodrug Conjugates
May 2022
in “
The FASEB journal
”
TLDR The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.
Current chemotherapy methods are non-specific and cause side effects like hair loss and lower blood cell count by killing both cancerous and healthy cells. Prodrug conjugates aim to target diseased cells specifically, reducing off-target effects. This study focuses on using vitamin receptor expression in tumor cells to design prodrug conjugates with biotin, folate, and RGD peptides as targeting groups. These conjugates include camptothecin, a naphthalimide fluorophore for tracking, and a disulfide linker that activates the drug in the cellular environment. The study is in the synthesis stage, aiming to compare the efficacy and specificity of these targeting groups.